Regulatory Science for Veterinary Therapeutic Innovation: A Comparative Analysis of Drug Development Incentives Within the One Health Framework.
- 1College of Veterinary Medicine, Chungbuk National University, Cheongju-si 28644, Republic of Korea.
- 2R&D Center, Rznomics, Inc., Seongnam-si 13486, Republic of Korea.
Abstract
Rapid advances in antiviral therapeutics, targeted biologics, RNA medicines, and precision veterinary medicine are generating unprecedented scientific opportunities for veterinary healthcare, yet translation of these innovations into approved veterinary products remains disproportionately slow. This review employs a comparative regulatory science framework to identify the regulatory and economic determinants of this innovation gap across four jurisdictions-FDA-CVM (US), EMA-CVMP (EU), PMDA/MAFF (Japan), and APVMA (Australia)-and to compare existing incentive instruments and identify the regulatory gaps between them. Two illustrative case studies, GS-441524 for feline infectious peritonitis and canine osteosarcoma therapeutics, illustrate how the absence of breakthrough pathways, limitations in the practical translation of Minor Use/Minor Species (MUMS) eligibility, and unresolved intellectual property barriers can suppress development investment. The multi-jurisdictional analysis indicates that this innovation gap is evident across the jurisdictions examined and is consistent with differences in the availability and strength of regulatory incentives, though scientific and market factors likely also contribute. Policy reforms are proposed, including a Veterinary Breakthrough Drug Designation, a One Health Innovation Designation with enhanced exclusivity, adaptive regulatory pathways, and strengthened VICH harmonization. Additionally, the regulatory preparedness for advanced veterinary therapeutics-including gene therapies, mRNA-based vaccines, and cell-based products-is examined as a critical frontier. The analysis highlights the role of regulatory science in translating emerging veterinary therapeutics into clinical practice within the One Health framework.
Related
- Engrailed-1 in eccrine sweat gland development and regeneration: from evolutionary innovation to therapeutic perspectives.
- Comparative Analysis of the Fatty Acid Profiles of Hypoallergenic Veterinary Diets, Commercial Dog Foods, and Oral Fatty Acid Supplements Available on the Hungarian Market
- Genome duplication and regulatory innovation underpin contrasting life-history strategies in cryptic Cassytha filiformis lineages
- Surveillance, Detection and Therapeutic Innovation in Antimicrobial Resistance in the Age of Polycrisis: From Genomic and Digital Innovation to One Health Integration
- Single-residue variation in the nucleosome core reveals a regulatory hub for phenotypic innovation
BibTeX
@article{hong2026regulatory,
title = {{Regulatory Science for Veterinary Therapeutic Innovation: A Comparative Analysis of Drug Development Incentives Within the One Health Framework.}},
author = {Sungwoo Hong and Sang-Myeong Lee},
journal = {Veterinary sciences},
year = {2026},
month = oct,
doi = {10.3390/vetsci13101119},
url = {https://europepmc.org/article/MED/42944213},
note = {CC BY},
}
RIS
TY - JOUR
TI - Regulatory Science for Veterinary Therapeutic Innovation: A Comparative Analysis of Drug Development Incentives Within the One Health Framework.
AU - Sungwoo Hong
AU - Sang-Myeong Lee
PY - 2026
DA - 2026/10/20
JO - Veterinary sciences
DO - 10.3390/vetsci13101119
UR - https://europepmc.org/article/MED/42944213
AB - Rapid advances in antiviral therapeutics, targeted biologics, RNA medicines, and precision veterinary medicine are generating unprecedented scientific opportunities for veterinary healthcare, yet translation of these innovations into approved veterinary products remains disproportionately slow. This review employs a comparative regulatory science framework to identify the regulatory and economic determinants of this innovation gap across four jurisdictions-FDA-CVM (US), EMA-CVMP (EU), PMDA/MAFF (Japan), and APVMA (Australia)-and to compare existing incentive instruments and identify the regulatory gaps between them. Two illustrative case studies, GS-441524 for feline infectious peritonitis and canine osteosarcoma therapeutics, illustrate how the absence of breakthrough pathways, limitations in the practical translation of Minor Use/Minor Species (MUMS) eligibility, and unresolved intellectual property barriers can suppress development investment. The multi-jurisdictional analysis indicates that this innovation gap is evident across the jurisdictions examined and is consistent with differences in the availability and strength of regulatory incentives, though scientific and market factors likely also contribute. Policy reforms are proposed, including a Veterinary Breakthrough Drug Designation, a One Health Innovation Designation with enhanced exclusivity, adaptive regulatory pathways, and strengthened VICH harmonization. Additionally, the regulatory preparedness for advanced veterinary therapeutics-including gene therapies, mRNA-based vaccines, and cell-based products-is examined as a critical frontier. The analysis highlights the role of regulatory science in translating emerging veterinary therapeutics into clinical practice within the One Health framework.
SN - 2306-7381
ER -